KROS
NASDAQ · Biotechnology
Keros Therapeutics Inc
$10.96
-0.16 (-1.44%)
Financial Highlights (FY 2026)
Revenue
2.46M
Net Income
-129,655,630
Gross Margin
—
Profit Margin
-5,277.6%
Rev Growth
-43.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 50.8% | 50.8% |
| Operating Margin | -5,939.0% | -5,345.1% | -16.0% | -16.9% |
| Profit Margin | -5,277.6% | -5,013.7% | -15.0% | -17.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.46M | 4.38M | 103.26M | 79.84M |
| Gross Profit | — | — | 52.49M | 40.58M |
| Operating Income | -145,867,331 | -233,970,055 | -16,499,040 | -13,532,511 |
| Net Income | -129,655,630 | -207,966,613 | -15,524,708 | -13,846,639 |
| Gross Margin | — | — | 50.8% | 50.8% |
| Operating Margin | -5,939.0% | -5,345.1% | -16.0% | -16.9% |
| Profit Margin | -5,277.6% | -5,013.7% | -15.0% | -17.3% |
| Rev Growth | -43.9% | -43.9% | +11.8% | -2.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 173.40M | 194.80M |
| Total Equity | — | — | 374.54M | 364.51M |
| D/E Ratio | — | — | 0.46 | 0.53 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -144,858,636 | -245,260,567 | -22,220,211 | -17,087,554 |
| Free Cash Flow | — | — | -17,331,210 | -15,756,938 |